Loading
CTO1681 is a tablet from CytoAgents meant to prevent and treat cytokine release syndrome, an immune over-reaction that can follow CAR-T cell therapy for blood cancers.
CTO1681 is CytoAgents' oral anti-inflammatory compound. ClinicalTrials.gov lists NCT05905328, a phase 1/2 study sponsored by CytoAgents of CTO1681 for the prevention and treatment of cytokine release syndrome in patients receiving CAR T-cell therapy, as recruiting. A 2026 National Cancer Institute SBIR award to CytoAgents extends the work to people with multiple myeloma receiving CAR T-cell therapy. It is a supportive medicine: it is not meant to treat the cancer itself.
Described by CytoAgents as a steroid-sparing inhibitor of prostaglandin and prostacyclin-mediated inflammation, given by mouth to damp the cytokine surge of cytokine release syndrome.
1.CTO1681 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CTO1681" OR ABSTRACT:"CTO1681" OR TITLE:"GP1681" OR ABSTRACT:"GP1681") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTO1681, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/